Theratechnologies joins Quartal and reports EBITDA forecast from Investing.com

Theratechnologies Inc. (TH.TO) achieved a net profit of US$3 million or US$0.06 pro Aktie was a German financial sector company in the quarter of 2024. The company has a higher forecast for higher EBITDA for the company.

Which knowledge:

– Q3 2024 Net Gain: US$3 million (US$0.06 pro Action)

– Umsatz: 22.6 million US dollars, 8% Steigerung in Jahresvergleich

– Cleaning EBITDA: US$7.2 million, Anstieg of US$2.2 million in Q3 2023

– Umsatz forecast for the average value of 83-85 million US dollars

– Forecast for expected EBITDA is US$17-19 million

Unternehmensausblick:

– Plant Einreichung eines Ergänzungsantrags für EGRIFTA SV Anfang November

– Erwartet erneute Einreichung der F8-Formulierung von Tesamorelin bis Ende November

– Rechnet mit Aufholung der losenen Verkäufe aus Q4 2024 Anfang 2025

– Focus on identifying new products and partnerships

Negative aspects:

– Temporary financing of production by CDMO

– Trogarzo-Verkäufe has sunk to US$5.9 million from US$7.7 million

– Erwartet langsamen Start in Q1 2025 aufgrund von Lagerabbau

Positive aspects:

– EGRIFTA SV Verkäufe takes 27% on an annual fee of US$16.7 million

– Strong liquidity position of quickly reaching US$39 million

– Heritage analysis of the cost structure

– Kredietvereinbarungsanforderungen with Marathon

Painting:

– An assessment of the Umsatzprognose aufgrund von Lieferengpässen

Highlights from the Fragerunde:

– Unternehmen erwartet Aufrechterhaltung der EBITDA-Nachhaltigkeit

– Rechnet mit Erholung der Verkäufe in Q1 2025 at Normalization of the Lagerbestände

– Trogarzo-Verkäufe sollen sich 2025 stabilizes

Theratechnologies secured solid financing for the 2024 quarter with net income of $3 million and realized EBITDA of $7.2 million. The value of the annual interest is 8% on 22.6 million US dollars, while one of the investments in the EGRIFTA SV sale is 27%.

Trotz Herausforderungen, eeninschließlich temporärer Lieferengpässe aufgrund einer freiwilligen Produktionsunterbrechung eines CDMO, bleibt Theratechnologies helps to increase their Zukunftsaussichten. The world is ignoring the average forecast for 2024 of 83-85 million US dollars and a high forecast for the clean EBITDA of 17-19 million US dollars for the gesamtjahr.

Theratechnologies plant, Anfang November einen Ergänzungsantrag für EGRIFTA SV einzureichen und erwartet, de F8-Formulierung von Tesamorelin bis Ende November erneut vorzulegen. Das Unternehmen rechnet damit, die im vierten Quartal 2024 verkäufe Anfang 2025 aufzuholen.

Während der Telefonkonferenz concretet das Management signals Focus on the Identifizierung new Productmöglichkeiten and Partnerschaften zur Wachstumssteigerung. The strong liquidity position of the fast US$39 million is being translated into these cuts.

Obwohl de Trogarzo-Verkäufe einen Rückgang verzeichneten, erwartet Theratechnologies eine Stabilsierung im year 2025. Das Unternehmen hob auch seine ergolgreiche Anpassung der Kostenstructure und de oververheid van kostenlosingsanorderungen with Marathon-revor.

For the Zukunft rechnet Theratechnologies with a langameren Start in the first quarter of 2025 on the Lagerabbau, erwartet jedoch an Erholung at Normalization of the Lagerbestände. The business community has a clear insight into the control of EBITDA compliance and the implementation of the Wachstumstrajektorie.

InvestingPro Acknowledgment

Theratechnologies Inc. (TH.TO) has published a German financial report in a number of annual reports, after which a genauerer can click on the InvestingPro data that offers some important nuances, making the investors more and more money.

Laut InvestingPro-Daten giving Theratechnologies a market cap of US$59.77 million was relatively small and their volatile share price was likely. If you want to use one of the InvestingPro tips, you can say that “Aktienkoersbewegungen are straight volatile”. This volatility can influence the unacceptable costs of the external economies, with a return of 5.18% in the week, after a minus of 28.94% in a year.

Due to the positive results of the investment tips, the analysts cannot expect that the companies will be profitable during that time. This prediction is not true, Theratechnologie will have considerable power, but can also receive a better revaluation with the achievement of constant profitability. The Kurs-Gewinn-Verhältnis (KGV) of -15.68 reflects this active unprofitable broader.

Positive for the brands is that the Thera technology is one of the most used results, with a number of messages of 25.46% to the quarter of 2024. This amount is boosted by the article message that 8% have received over time. Darüber has passed the EBITDA value of 140.45% in the last month of the 2024 quarter to send messages about the realized EBITDA of the other companies.

For investors making such an analysis, InvestingPro offers 11 other tips for theratechnologies, one of the many financial advantages and market positions of their external economies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.